The NEMO Project
 |
The efficacy of several medications for treating newborn seizures is being trialled in an EU FP7 funded project entitled "Treatment of neonatal seizures with medication off-patent: Evaluation of efficacy and safety of bumetanide"- or NEMO for short. NEMO is an EU FP7 funded project that will be the largest multicentered European study of neonatal seizures and their treatment. The project addresses the FP7 Health call ‘Adapting off-patent medicines to the specific needs of paediatric populations’ by investigating the safety and efficacy of bumetanide for the treatment of seizures in babies. Bumetanide is included in the European Medicines Agency (EMEA) revised priority list for studies into off-patent paediatric medicinal products. The aim of the project is to develop a safe and effective antiepileptic drug (AED) regimen for newborn babies with seizures. Seizures are the most common neurological emergency in the neonatal period and require prompt diagnosis and treatment. The project will evaluate the safety and efficacy of bumetanide in combination with phenobarbitone for seizure control using: preclinical studies, a multicentre clinical trial with multichannel EEG monitoring, pharmacokinetic studies and outcome assessment. More information on the NEMO trial can be found here.
|
|
